Based on results from ADAURA, in clinical practice, how likely are you to recommend adjuvant chemotherapy prior to adjuvant osimertinib for stage IIA T2bN0 EGFR mutant NSCLC?

I am unlikely to recommend adjuvant chemotherapy prior to Osimertinib. The 24-month disease-free survival for patients on Osimertinib was identical (89%) regardless of adjuvant chemotherapy administration. Unless long term data shows a significant benefit, I would not recommend adjuvant chemotherapy...